Insight

Shankar Siva about the results of DESTROY-2 trial

iconcancercentre.com.au

Oct 29, 2024, 12:51

Shankar Siva about the results of DESTROY-2 trial

Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre, shared a post on X about a recent paper by F. Deodato et al. published in Clinical Oncology.

“DESTROY-2 trial. A quick reminder to those who worry about side effects with single fraction SABR – only 1x Grade 3 adverse event after 227 courses of stereotactic body radiotherapy. It can be done safely!”

Michael Chuong, Professor at Florida International University’s Herbert Wertheim College of Medicine, shared this post, adding:

“Our ph2 SMART ONE trial (mostly liver, adrenal, abdominal LN, 25-40 Gy x 1) also showed:

Safety: only 1 possibly related Gr3 AE
Efficacy: 1-yr LC 100%
Manuscript submission pending

Working on some interesting single fraction SABR trial concepts…stay tuned.”

“Stereotactic Radiosurgery with Volumetric Modulated Arc Radiotherapy: Final Results of a Multi-arm Phase I Trial (DESTROY-2)”

Authors: F. Deodato, D. Pezzulla, S. Cilla, C. Romano, Mi. Ferro, E. Galietta, V. Lancellotta, A.G. Morganti, G. Macchia

Shankar Siva about the results of DESTROY-2 trial

More posts featuring Shankar Siva and Michael Chuong.

Michael Chuong is the GI Section Editor for the International Journal of Radiation Oncology Biology Physics. He is a Professor at Florida International University’s Herbert Wertheim College of Medicine and serves as the Vice Chair and Medical Director of the Department of Radiation Oncology at the Miami Cancer Institute.

Additionally, he is the Chief of the GI Radiation Oncology Service at Baptist Health South Florida, specializing in the treatment of gastrointestinal cancers.